Actinium Pharmaceuticals Inc (ATNM)

[blukky]

Oppenheimer Maintains Their Buy Rating on Actinium Pharmaceuticals (ATNM)

Austin Angelo-August 16, 2018, 7:51 AM EDTSHARE ON:

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM), with a price target of $5. The company’s shares closed yesterday at $0.62.

Singh wrote:

“Actinium Pharmaceuticals (ATNM) held a conference call this morning to update investors on the ongoing pivotal Phase 3 SIERRA study of Iomab-B in r/r AML. Management disclosed a positive DMC analysis following the 25% enrollment mark, and additional protocol amendments as a result of feedback from the clinical investigators. We believe these ongoing collaborative efforts with investigators will optimize SIERRA and reflect the underlying support of the physician/KOL community. This trial readout is expected by YE19, but could occur sooner. Changes to the protocol have strengthened the potential product profile and site operational dynamics. We update our model for 2Q18 financials and remain bullish.”